Yao Lin TLDR A peptide can produce striking results in mice and later show little benefit in people. That is not unusual, and it does not necessarily mean anyone made a mistake. Animal studies answer an important question: what does this experimental molecule do in this animal model under these conditions? Human clinical research asks a related … Read more
Retatrutide research initially attracted attention because of the amount of weight participants lost. But the Phase 3 research program is increasingly asking a different question: What happens to the health conditions associated with obesity when body weight falls by 20%, 25%, or even more? By mid-2026, retatrutide had produced reported improvements in several areas beyond … Read more
TLDR A paper can be technically accurate and still be easy to misread. Suppose the headline says: “Peptide X reduced tumor growth by 60%.” That sounds impressive. But before deciding what it means, we need to know whether the experiment involved: a purified enzyme, a dish of cancer cells, a mouse xenograft, twenty patients, or … Read more
Glucagon has traditionally been associated with one thing: raising blood glucose. So it can sound counterintuitive that retatrutide, a molecule being studied for obesity and type 2 diabetes, was deliberately designed to activate the glucagon receptor. That receptor activity is not an accidental side effect. It is one of the defining features of retatrutide. Retatrutide, … Read more
TLDR Retatrutide has now produced significant improvements in both glycemic control and body weight in peer-reviewed Phase 2 and Phase 3 trials involving people with type 2 diabetes. The 2023 Phase 2 study found A1C reductions of about 2 percentage points at the higher doses and weight loss approaching 17% after 36 weeks. The evidence … Read more
TLDR A peptide can have the correct sequence when it is synthesized and still become a chemically different material later. Sometimes a bond breaks. Sometimes an amino acid side chain is oxidized. Sometimes an asparagine residue rearranges. And sometimes the peptide remains chemically unchanged but begins associating with other peptide molecules until aggregates or fibrils … Read more
Updated September 4, 2026 Retatrutide is no longer a drug candidate supported by one or two promising trials. Eli Lilly has built a broad clinical development program around the investigational triple hormone receptor agonist, testing it across obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, obstructive sleep apnea, knee osteoarthritis, chronic low back pain, … Read more
TLDR Semaglutide is a peptide. So is retatrutide. So are insulin, glucagon, liraglutide, teriparatide, oxytocin, and many other biologically active molecules. But saying that two products “contain peptides” tells us very little about their regulatory or pharmaceutical status. A research peptide sold as a laboratory reagent and an FDA-approved peptide medicine may even contain nominally … Read more
Retatrutide’s Phase 3 results are now large enough that one number no longer describes the drug. Depending on which trial you look at, the highest-dose retatrutide group lost an average of about 20.8%, 22.6%, 28.3%, or 28.7% of body weight. Those differences are not contradictions. They come from four trials that studied very different people. … Read more
Retatrutide has now been studied in thousands of people across Phase 2 and Phase 3 clinical trials. That gives researchers a much clearer picture of its safety profile than was available when the first obesity results appeared in 2023. The most consistent finding is not surprising: gastrointestinal side effects are the most common adverse events, … Read more
TLDR A peptide stability study is really a study of change. Researchers begin with a characterized peptide and repeatedly ask the same question: Is it still the same material? That sounds simple until we define what “same” means. A peptide could retain 99% chromatographic purity while forming a small amount of aggregate. It could maintain … Read more
Large reductions in body weight almost never come entirely from body fat. Some fat-free mass is usually lost as well. That has made muscle loss an important question for newer incretin-based drugs, especially retatrutide, which has produced particularly large weight reductions in clinical trials. The good news is that researchers now have direct body-composition data … Read more
TLDR Retatrutide, tirzepatide, and semaglutide act on different combinations of metabolic hormone receptors. Semaglutide: GLP-1 receptor agonist. Tirzepatide: GIP + GLP-1 receptor agonist. Retatrutide: GIP + GLP-1 + glucagon receptor agonist. In separate obesity trials without diabetes, semaglutide produced about 14.9% average weight loss at 68 weeks in STEP 1, tirzepatide produced up to 20.9% … Read more
TLDR Peptide concentration describes how much peptide is present in a given volume of solution. For injectable preparations, it is commonly expressed as milligrams per milliliter, or mg/mL. The basic relationship is: Concentration = amount of peptide ÷ final volume So a solution containing 10 mg of peptide per 1 mL has a concentration of … Read more
TLDR Retatrutide has produced unusually large reductions in liver fat in a peer-reviewed randomized Phase 2a substudy involving people with obesity or overweight and metabolic dysfunction-associated steatotic liver disease, or MASLD. Among 98 participants with at least 10% liver fat by MRI-PDFF, average relative liver-fat reductions after 24 weeks were 42.9%, 57.0%, 81.4%, and 82.4% … Read more
